Literature DB >> 21415814

Short-term reproducibility of ambulatory blood pressure monitoring in autosomal dominant polycystic kidney disease.

Frederic F Rahbari-Oskoui1, Dana C Miskulin, Marie C Hogan, Odicie Fielder, Vicente E Torres, James E Bost, Arlene Beth Chapman.   

Abstract

BACKGROUND AND OBJECTIVES: Nondipping, defined as a less than 10% decline in Night:Day (N:D) ratio of blood pressure using 24 h ambulatory blood pressure monitoring, is associated with poor cardiovascular outcomes. However, its reproducibility has been questioned in autosomal dominant polycystic kidney disease.
MATERIALS AND METHODS: Twenty-five of 29 recruited hypertensive or prehypertensive patients with autosomal dominant polycystic kidney disease completed ambulatory blood pressure monitoring on two occasions, 7-15 days apart, on a stable antihypertensive regimen. Daytime and night-time were defined as 6:00-21:59 h and 22:00-5:59 h, respectively. Correlation and concordance coefficients for systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate were determined based on N:D and Asleep:Awake (A:A) ratios. Consistency of dipping was assessed by using Cohen's Kappa statistics.
RESULTS: Mean (±standard deviation) for age, estimated glomerular filtration rate, differences in daytime and night-time SBP and DBP were 43.12 years (8.55 years), 63.1 ml/min (20.5 ml/min), 11.74 mmHg (8.2 mmHg), and 10.82 mmHg (6.4 mmHg), respectively. Seventeen of 25 (68%) and 18 of 25 (72%) participants maintained the same dipping category based on D:N or A:A separation. Cohen's Kappa was 0.34 for D:N ratio and 0.38 for A:A ratio. Correlation and concordance coefficients were 0.89 and 0.88 for daytime SBP, 0.91 and 0.91 for daytime DBP, 0.79 and 0.78 for night-time SBP, 0.81 and 0.80 for night-time DBP, 0.58 and 0.56 for N:D ratio of SBP, and 0.56 and 0.53 for N:D ratio of DBP. Coefficients for A:A ratio were almost identical to N:D values except for A:A ratios of SBP (0.69 and 0.67) and DBP (0.48 and 0.45).
CONCLUSION: Repeated measures of SBP and DBP, 7-15 days apart, are highly correlative and concordant in the studied population, but nondipping, even though predominant, was found to be modestly reproducible.

Entities:  

Mesh:

Year:  2011        PMID: 21415814      PMCID: PMC3061024          DOI: 10.1097/MBP.0b013e328344c6f3

Source DB:  PubMed          Journal:  Blood Press Monit        ISSN: 1359-5237            Impact factor:   1.444


  45 in total

Review 1.  Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects.

Authors:  Tevfik Ecder; Robert W Schrier
Journal:  J Am Soc Nephrol       Date:  2001-01       Impact factor: 10.121

Review 2.  Cystic and inherited kidney diseases.

Authors:  Dana Rizk; Arlene B Chapman
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

3.  A concordance correlation coefficient to evaluate reproducibility.

Authors:  L I Lin
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

4.  The reproducibility of the circadian BP rhythm in treated hypertensive patients with polycystic kidney disease and mild chronic renal impairment--a prospective ABPM study.

Authors:  Adrian Covic; Irina Mititiuc; Paul Gusbeth-Tatomir; David J Goldsmith
Journal:  J Nephrol       Date:  2002 Sep-Oct       Impact factor: 3.902

5.  Ambulatory blood pressure in hypertensive patients with autosomal dominant polycystic kidney disease.

Authors:  T C Li Kam Wa; A M Macnicol; M L Watson
Journal:  Nephrol Dial Transplant       Date:  1997-10       Impact factor: 5.992

6.  Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study.

Authors:  Hirohito Metoki; Takayoshi Ohkubo; Masahiro Kikuya; Kei Asayama; Taku Obara; Junichiro Hashimoto; Kazuhito Totsune; Haruhisa Hoshi; Hiroshi Satoh; Yutaka Imai
Journal:  Hypertension       Date:  2005-12-27       Impact factor: 10.190

7.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

8.  Cardiovascular target organ damage in essential hypertensives with or without reproducible nocturnal fall in blood pressure.

Authors:  Cesare Cuspidi; Stefano Meani; Maurizio Salerno; Cristiana Valerio; Veronica Fusi; Barbara Severgnini; Laura Lonati; Fabio Magrini; Alberto Zanchetti
Journal:  J Hypertens       Date:  2004-02       Impact factor: 4.844

9.  Factors affecting ambulatory blood pressure reproducibility. Results of the HARVEST Trial. Hypertension and Ambulatory Recording Venetia Study.

Authors:  P Palatini; P Mormino; C Canali; M Santonastaso; G De Venuto; G Zanata; A C Pessina
Journal:  Hypertension       Date:  1994-02       Impact factor: 10.190

10.  Neurohumoral characteristics of older hypertensive patients with abnormal nocturnal blood pressure dipping.

Authors:  Kazuomi Kario; Takeshi Mitsuhashi; Kazuyuki Shimada
Journal:  Am J Hypertens       Date:  2002-06       Impact factor: 2.689

View more
  3 in total

1.  A young patient with a family history of hypertension.

Authors:  Aldo J Peixoto
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-04       Impact factor: 8.237

Review 2.  Interventions for preventing the progression of autosomal dominant polycystic kidney disease.

Authors:  Davide Bolignano; Suetonia C Palmer; Marinella Ruospo; Carmine Zoccali; Jonathan C Craig; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14

3.  Short-term reproducibility of ambulatory blood pressure measurements: a systematic review and meta-analysis of 35 observational studies.

Authors:  Yacong Bo; Kin-On Kwok; Vincent Chi-Ho Chung; Chun-Pong Yu; Kelvin Kam-Fai Tsoi; Samuel Yeung-Shan Wong; Eric Kam-Pui Lee
Journal:  J Hypertens       Date:  2020-11       Impact factor: 4.776

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.